drugset / Trial / NCT07454837
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2b/3, randomized, open-label, multicenter trial evaluating the efficacy and safety of switching from bulevirtide to brelovitug for the treatment of chronic hepatitis Delta infection (CHD).
Timeline
- Start
- 2026-02-26
- Primary completion
- 2027-08-31
- Completion
- 2029-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brelovitug | Unknown | 300 mg | Subcutaneous |
| Background | Bulevirtide | Protein / enzyme biologic | — | — |